review Open AccessTop 1% cited
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
Alimentary Pharmacology & Therapeutics · 2008 · Vol. 28(9) · pp. 1067–1077
Joseph J.�Y. Sung✉(Chinese University of Hong Kong)Kelvin Tsoi(Prince of Wales Hospital)Vincent Wai‐Sun Wong(Prince of Wales Hospital)K. C. T. LI(Prince of Wales Hospital)Henry Lik‐Yuen Chan(Chinese University of Hong Kong)
Abstract
IFN or NA treatment significantly reduces risk of HCC. While IFN benefited patients with cirrhosis, NA benefited patients with no cirrhosis and HBeAg-positive CHB infection.
Hepatitis B Virus StudiesHepatitis C virus researchLiver Disease Diagnosis and TreatmentMedicineHepatocellular carcinomaCirrhosisInternal medicineGastroenterologyRelative riskHBeAgHepatitis BRandomized controlled trialHepatitis B virus
MeSH terms
Carcinoma, HepatocellularHumansInterferonsLiver CirrhosisNucleosidesNucleotidesRisk FactorsRandomized Controlled Trials as TopicHepatitis B, Chronic
Citations
371
FWCI
13.64
field-weighted impact
References
44
Percentile
99%
vs. same field & year
Citations per year
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Journal of Hepatology · 2018 · 11,335 citations
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Journal of Cancer · 2012 · 1,107 citations
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
Journal of Hepatology · 2012 · 5,186 citations
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Gastroenterology · 2012 · 3,378 citations
Epidemiology and Management of Hepatocellular Carcinoma
Gastroenterology · 2018 · 1,819 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.